Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Starts Trials of Bispecific Antibody for Severe Asthma

publication date: Mar 1, 2024

Suzhou Innovent Biologics dosed the first patient in an Australian Phase I trial of IBI3002, a global first-in-class bispecific antibody for asthma. IBI3002 is a humanized bispecific antibody that targets cell surface IL-4Rα and the alarmin cytokine TSLP, discovered by Innovent to treat inflammatory diseases, including asthma. TSLP is an epithelial cell-derived alarmin cytokine that triggers both T2 and non-T2 inflammation in asthma. Innovent believes IBI3002, with its dual targets, has the potential to treat several inflammatory diseases. Innovent develops novel medicines for oncology, metabolic, autoimmune and ophthalmology indications. More details....

Stock Symbol: (HKEX: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here